The Claim
Reductions in dp-ucMGP levels following vitamin K2 supplementation in hemodialysis patients are not consistently correlated with reductions in vascular calcification across studies.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In hemodialysis patients, lowering dp-ucMGP levels with vitamin K2 supplements does not consistently lead to reduced vascular calcification across different studies.
See the scientific wording
The reduction in dp-ucMGP levels following vitamin K2 supplementation in hemodialysis patients does not consistently correlate with reductions in vascular calcification across studies, suggesting that vitamin K deficiency may not be the primary driver of calcification in this population.
Vitamin K2 activates a protein in blood vessel walls that binds to calcium and stops it from building up in the arteries. Even when this protein is fully activated, calcium still builds up because other factors are stronger drivers of the process.
What the research says
1 studyGiving vitamin K2 pills lowered a blood marker of vitamin K deficiency in dialysis patients, but their arteries didn't get less calcified. This means the vitamin K problem might not be the main reason their arteries harden.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.